Global Anti-Obesity Therapeutics Market Research Report 2024

Report ID: 1975391 | Published Date: Oct 2024 | No. of Page: 98 | Base Year: 2023 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Anti-Obesity Therapeutics Market Overview
    1.1 Product Overview and Scope of Anti-Obesity Therapeutics
    1.2 Anti-Obesity Therapeutics Segment by Type
        1.2.1 Global Anti-Obesity Therapeutics Sales Growth Rate Comparison by Type (2022-2028)
        1.2.2 Centrally Acting Anti-obesity Drugs
        1.2.3 Peripherally Acting Anti-obesity Drugs
    1.3 Anti-Obesity Therapeutics Segment by Application
        1.3.1 Global Anti-Obesity Therapeutics Sales Comparison by Application: (2022-2028)
        1.3.2 Hospital Use
        1.3.3 Clinic Use
        1.3.4 Household
        1.3.5 Other
    1.4 Global Anti-Obesity Therapeutics Market Size Estimates and Forecasts
        1.4.1 Global Anti-Obesity Therapeutics Revenue 2017-2028
        1.4.2 Global Anti-Obesity Therapeutics Sales 2017-2028
        1.4.3 Anti-Obesity Therapeutics Market Size by Region: 2017 Versus 2021 Versus 2028
2 Anti-Obesity Therapeutics Market Competition by Manufacturers
    2.1 Global Anti-Obesity Therapeutics Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Anti-Obesity Therapeutics Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Anti-Obesity Therapeutics Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Anti-Obesity Therapeutics Manufacturing Sites, Area Served, Product Type
    2.5 Anti-Obesity Therapeutics Market Competitive Situation and Trends
        2.5.1 Anti-Obesity Therapeutics Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Anti-Obesity Therapeutics Players Market Share by Revenue
        2.5.3 Global Anti-Obesity Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-Obesity Therapeutics Retrospective Market Scenario by Region
    3.1 Global Anti-Obesity Therapeutics Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Anti-Obesity Therapeutics Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Anti-Obesity Therapeutics Market Facts & Figures by Country
        3.3.1 North America Anti-Obesity Therapeutics Sales by Country
        3.3.2 North America Anti-Obesity Therapeutics Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Anti-Obesity Therapeutics Market Facts & Figures by Country
        3.4.1 Europe Anti-Obesity Therapeutics Sales by Country
        3.4.2 Europe Anti-Obesity Therapeutics Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Anti-Obesity Therapeutics Market Facts & Figures by Region
        3.5.1 Asia Pacific Anti-Obesity Therapeutics Sales by Region
        3.5.2 Asia Pacific Anti-Obesity Therapeutics Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America Anti-Obesity Therapeutics Market Facts & Figures by Country
        3.6.1 Latin America Anti-Obesity Therapeutics Sales by Country
        3.6.2 Latin America Anti-Obesity Therapeutics Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Anti-Obesity Therapeutics Market Facts & Figures by Country
        3.7.1 Middle East and Africa Anti-Obesity Therapeutics Sales by Country
        3.7.2 Middle East and Africa Anti-Obesity Therapeutics Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 U.A.E
4 Global Anti-Obesity Therapeutics Historic Market Analysis by Type
    4.1 Global Anti-Obesity Therapeutics Sales Market Share by Type (2017-2022)
    4.2 Global Anti-Obesity Therapeutics Revenue Market Share by Type (2017-2022)
    4.3 Global Anti-Obesity Therapeutics Price by Type (2017-2022)
5 Global Anti-Obesity Therapeutics Historic Market Analysis by Application
    5.1 Global Anti-Obesity Therapeutics Sales Market Share by Application (2017-2022)
    5.2 Global Anti-Obesity Therapeutics Revenue Market Share by Application (2017-2022)
    5.3 Global Anti-Obesity Therapeutics Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Bristol-Myers Squibb
        6.1.1 Bristol-Myers Squibb Corporation Information
        6.1.2 Bristol-Myers Squibb Description and Business Overview
        6.1.3 Bristol-Myers Squibb Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Bristol-Myers Squibb Anti-Obesity Therapeutics Product Portfolio
        6.1.5 Bristol-Myers Squibb Recent Developments/Updates
    6.2 Eisai Company
        6.2.1 Eisai Company Corporation Information
        6.2.2 Eisai Company Description and Business Overview
        6.2.3 Eisai Company Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Eisai Company Anti-Obesity Therapeutics Product Portfolio
        6.2.5 Eisai Company Recent Developments/Updates
    6.3 FlaxoSithKline plc.
        6.3.1 FlaxoSithKline plc. Corporation Information
        6.3.2 FlaxoSithKline plc. Description and Business Overview
        6.3.3 FlaxoSithKline plc. Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 FlaxoSithKline plc. Anti-Obesity Therapeutics Product Portfolio
        6.3.5 FlaxoSithKline plc. Recent Developments/Updates
    6.4 Novo Nordisk
        6.4.1 Novo Nordisk Corporation Information
        6.4.2 Novo Nordisk Description and Business Overview
        6.4.3 Novo Nordisk Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Novo Nordisk Anti-Obesity Therapeutics Product Portfolio
        6.4.5 Novo Nordisk Recent Developments/Updates
    6.5 Alizyme
        6.5.1 Alizyme Corporation Information
        6.5.2 Alizyme Description and Business Overview
        6.5.3 Alizyme Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 Alizyme Anti-Obesity Therapeutics Product Portfolio
        6.5.5 Alizyme Recent Developments/Updates
    6.6 BoehringerIngelheim GmbH
        6.6.1 BoehringerIngelheim GmbH Corporation Information
        6.6.2 BoehringerIngelheim GmbH Description and Business Overview
        6.6.3 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product Portfolio
        6.6.5 BoehringerIngelheim GmbH Recent Developments/Updates
    6.7 Pfizer
        6.6.1 Pfizer Corporation Information
        6.6.2 Pfizer Description and Business Overview
        6.6.3 Pfizer Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Pfizer Anti-Obesity Therapeutics Product Portfolio
        6.7.5 Pfizer Recent Developments/Updates
    6.8 Takeda Pharmaceutical
        6.8.1 Takeda Pharmaceutical Corporation Information
        6.8.2 Takeda Pharmaceutical Description and Business Overview
        6.8.3 Takeda Pharmaceutical Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 Takeda Pharmaceutical Anti-Obesity Therapeutics Product Portfolio
        6.8.5 Takeda Pharmaceutical Recent Developments/Updates
    6.9 Rhythm Pharmaceuticals
        6.9.1 Rhythm Pharmaceuticals Corporation Information
        6.9.2 Rhythm Pharmaceuticals Description and Business Overview
        6.9.3 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product Portfolio
        6.9.5 Rhythm Pharmaceuticals Recent Developments/Updates
    6.10 Shionogi USA
        6.10.1 Shionogi USA Corporation Information
        6.10.2 Shionogi USA Description and Business Overview
        6.10.3 Shionogi USA Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 Shionogi USA Anti-Obesity Therapeutics Product Portfolio
        6.10.5 Shionogi USA Recent Developments/Updates
    6.11 Vivus
        6.11.1 Vivus Corporation Information
        6.11.2 Vivus Anti-Obesity Therapeutics Description and Business Overview
        6.11.3 Vivus Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 Vivus Anti-Obesity Therapeutics Product Portfolio
        6.11.5 Vivus Recent Developments/Updates
    6.12 Zafgen
        6.12.1 Zafgen Corporation Information
        6.12.2 Zafgen Anti-Obesity Therapeutics Description and Business Overview
        6.12.3 Zafgen Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 Zafgen Anti-Obesity Therapeutics Product Portfolio
        6.12.5 Zafgen Recent Developments/Updates
    6.13 Norgine Pharmaceuticals Ltd.
        6.13.1 Norgine Pharmaceuticals Ltd. Corporation Information
        6.13.2 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Description and Business Overview
        6.13.3 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2017-2022)
        6.13.4 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product Portfolio
        6.13.5 Norgine Pharmaceuticals Ltd. Recent Developments/Updates
7 Anti-Obesity Therapeutics Manufacturing Cost Analysis
    7.1 Anti-Obesity Therapeutics Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Anti-Obesity Therapeutics
    7.4 Anti-Obesity Therapeutics Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Anti-Obesity Therapeutics Distributors List
    8.3 Anti-Obesity Therapeutics Customers
9 Anti-Obesity Therapeutics Market Dynamics
    9.1 Anti-Obesity Therapeutics Industry Trends
    9.2 Anti-Obesity Therapeutics Market Drivers
    9.3 Anti-Obesity Therapeutics Market Challenges
    9.4 Anti-Obesity Therapeutics Market Restraints
10 Global Market Forecast
    10.1 Anti-Obesity Therapeutics Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Anti-Obesity Therapeutics by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Anti-Obesity Therapeutics by Type (2023-2028)
    10.2 Anti-Obesity Therapeutics Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Anti-Obesity Therapeutics by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Anti-Obesity Therapeutics by Application (2023-2028)
    10.3 Anti-Obesity Therapeutics Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Anti-Obesity Therapeutics by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Anti-Obesity Therapeutics by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables
    Table 1. Global Anti-Obesity Therapeutics Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
    Table 2. Global Anti-Obesity Therapeutics Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
    Table 3. Global Anti-Obesity Therapeutics Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Anti-Obesity Therapeutics Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Anti-Obesity Therapeutics Sales (K Units) of Key Manufacturers (2017-2022)
    Table 6. Global Anti-Obesity Therapeutics Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Anti-Obesity Therapeutics Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Anti-Obesity Therapeutics Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Anti-Obesity Therapeutics Average Price (USD/Unit) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Anti-Obesity Therapeutics Manufacturing Sites and Area Served
    Table 11. Manufacturers Anti-Obesity Therapeutics Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Anti-Obesity Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Obesity Therapeutics as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Anti-Obesity Therapeutics Sales by Region (2017-2022) & (K Units)
    Table 16. Global Anti-Obesity Therapeutics Sales Market Share by Region (2017-2022)
    Table 17. Global Anti-Obesity Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Anti-Obesity Therapeutics Revenue Market Share by Region (2017-2022)
    Table 19. North America Anti-Obesity Therapeutics Sales by Country (2017-2022) & (K Units)
    Table 20. North America Anti-Obesity Therapeutics Sales Market Share by Country (2017-2022)
    Table 21. North America Anti-Obesity Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Anti-Obesity Therapeutics Revenue Market Share by Country (2017-2022)
    Table 23. Europe Anti-Obesity Therapeutics Sales by Country (2017-2022) & (K Units)
    Table 24. Europe Anti-Obesity Therapeutics Sales Market Share by Country (2017-2022)
    Table 25. Europe Anti-Obesity Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Anti-Obesity Therapeutics Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Anti-Obesity Therapeutics Sales by Region (2017-2022) & (K Units)
    Table 28. Asia Pacific Anti-Obesity Therapeutics Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Anti-Obesity Therapeutics Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Anti-Obesity Therapeutics Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Anti-Obesity Therapeutics Sales by Country (2017-2022) & (K Units)
    Table 32. Latin America Anti-Obesity Therapeutics Sales Market Share by Country (2017-2022)
    Table 33. Latin America Anti-Obesity Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Anti-Obesity Therapeutics Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Anti-Obesity Therapeutics Sales by Country (2017-2022) & (K Units)
    Table 36. Middle East and Africa Anti-Obesity Therapeutics Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Anti-Obesity Therapeutics Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Anti-Obesity Therapeutics Revenue Market Share by Country (2017-2022)
    Table 39. Global Anti-Obesity Therapeutics Sales by Type (2017-2022) & (K Units)
    Table 40. Global Anti-Obesity Therapeutics Sales Market Share by Type (2017-2022)
    Table 41. Global Anti-Obesity Therapeutics Revenue by Type (2017-2022) & (US$ Million)
    Table 42. Global Anti-Obesity Therapeutics Revenue Share by Type (2017-2022)
    Table 43. Global Anti-Obesity Therapeutics Price by Type (2017-2022) & (USD/Unit)
    Table 44. Global Anti-Obesity Therapeutics Sales (K Units) by Application (2017-2022)
    Table 45. Global Anti-Obesity Therapeutics Sales Market Share by Application (2017-2022)
    Table 46. Global Anti-Obesity Therapeutics Revenue by Application (2017-2022) & (US$ Million)
    Table 47. Global Anti-Obesity Therapeutics Revenue Share by Application (2017-2022)
    Table 48. Global Anti-Obesity Therapeutics Price by Application (2017-2022) & (USD/Unit)
    Table 49. Bristol-Myers Squibb Corporation Information
    Table 50. Bristol-Myers Squibb Description and Business Overview
    Table 51. Bristol-Myers Squibb Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 52. Bristol-Myers Squibb Anti-Obesity Therapeutics Product
    Table 53. Bristol-Myers Squibb Recent Developments/Updates
    Table 54. Eisai Company Corporation Information
    Table 55. Eisai Company Description and Business Overview
    Table 56. Eisai Company Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 57. Eisai Company Anti-Obesity Therapeutics Product
    Table 58. Eisai Company Recent Developments/Updates
    Table 59. FlaxoSithKline plc. Corporation Information
    Table 60. FlaxoSithKline plc. Description and Business Overview
    Table 61. FlaxoSithKline plc. Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 62. FlaxoSithKline plc. Anti-Obesity Therapeutics Product
    Table 63. FlaxoSithKline plc. Recent Developments/Updates
    Table 64. Novo Nordisk Corporation Information
    Table 65. Novo Nordisk Description and Business Overview
    Table 66. Novo Nordisk Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 67. Novo Nordisk Anti-Obesity Therapeutics Product
    Table 68. Novo Nordisk Recent Developments/Updates
    Table 69. Alizyme Corporation Information
    Table 70. Alizyme Description and Business Overview
    Table 71. Alizyme Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 72. Alizyme Anti-Obesity Therapeutics Product
    Table 73. Alizyme Recent Developments/Updates
    Table 74. BoehringerIngelheim GmbH Corporation Information
    Table 75. BoehringerIngelheim GmbH Description and Business Overview
    Table 76. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 77. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product
    Table 78. BoehringerIngelheim GmbH Recent Developments/Updates
    Table 79. Pfizer Corporation Information
    Table 80. Pfizer Description and Business Overview
    Table 81. Pfizer Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 82. Pfizer Anti-Obesity Therapeutics Product
    Table 83. Pfizer Recent Developments/Updates
    Table 84. Takeda Pharmaceutical Corporation Information
    Table 85. Takeda Pharmaceutical Description and Business Overview
    Table 86. Takeda Pharmaceutical Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 87. Takeda Pharmaceutical Anti-Obesity Therapeutics Product
    Table 88. Takeda Pharmaceutical Recent Developments/Updates
    Table 89. Rhythm Pharmaceuticals Corporation Information
    Table 90. Rhythm Pharmaceuticals Description and Business Overview
    Table 91. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 92. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product
    Table 93. Rhythm Pharmaceuticals Recent Developments/Updates
    Table 94. Shionogi USA Corporation Information
    Table 95. Shionogi USA Description and Business Overview
    Table 96. Shionogi USA Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 97. Shionogi USA Anti-Obesity Therapeutics Product
    Table 98. Shionogi USA Recent Developments/Updates
    Table 99. Vivus Corporation Information
    Table 100. Vivus Description and Business Overview
    Table 101. Vivus Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 102. Vivus Anti-Obesity Therapeutics Product
    Table 103. Vivus Recent Developments/Updates
    Table 104. Zafgen Corporation Information
    Table 105. Zafgen Description and Business Overview
    Table 106. Zafgen Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 107. Zafgen Anti-Obesity Therapeutics Product
    Table 108. Zafgen Recent Developments/Updates
    Table 109. Norgine Pharmaceuticals Ltd. Corporation Information
    Table 110. Norgine Pharmaceuticals Ltd. Description and Business Overview
    Table 111. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 112. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product
    Table 113. Norgine Pharmaceuticals Ltd. Recent Developments/Updates
    Table 114. Production Base and Market Concentration Rate of Raw Material
    Table 115. Key Suppliers of Raw Materials
    Table 116. Anti-Obesity Therapeutics Distributors List
    Table 117. Anti-Obesity Therapeutics Customers List
    Table 118. Anti-Obesity Therapeutics Market Trends
    Table 119. Anti-Obesity Therapeutics Market Drivers
    Table 120. Anti-Obesity Therapeutics Market Challenges
    Table 121. Anti-Obesity Therapeutics Market Restraints
    Table 122. Global Anti-Obesity Therapeutics Sales Forecast by Type (2023-2028) & (K Units)
    Table 123. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Type (2023-2028)
    Table 124. Global Anti-Obesity Therapeutics Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 125. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Type (2023-2028)
    Table 126. Global Anti-Obesity Therapeutics Sales Forecast by Application (2023-2028) & (K Units)
    Table 127. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Application (2023-2028)
    Table 128. Global Anti-Obesity Therapeutics Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 129. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Application (2023-2028)
    Table 130. Global Anti-Obesity Therapeutics Sales Forecast by Region (2023-2028) & (K Units)
    Table 131. Global Anti-Obesity Therapeutics Sales Market Share Forecast by Region (2023-2028)
    Table 132. Global Anti-Obesity Therapeutics Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 133. Global Anti-Obesity Therapeutics Revenue Market Share Forecast by Region (2023-2028)
    Table 134. Research Programs/Design for This Report
    Table 135. Key Data Information from Secondary Sources
    Table 136. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Anti-Obesity Therapeutics
    Figure 2. Global Anti-Obesity Therapeutics Market Share by Type in 2021 & 2028
    Figure 3. Centrally Acting Anti-obesity Drugs Product Picture
    Figure 4. Peripherally Acting Anti-obesity Drugs Product Picture
    Figure 5. Global Anti-Obesity Therapeutics Market Share by Application in 2021 & 2028
    Figure 6. Hospital Use
    Figure 7. Clinic Use
    Figure 8. Household
    Figure 9. Other
    Figure 10. Global Anti-Obesity Therapeutics Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 11. Global Anti-Obesity Therapeutics Market Size (2017-2028) & (US$ Million)
    Figure 12. Global Anti-Obesity Therapeutics Sales (2017-2028) & (K Units)
    Figure 13. Anti-Obesity Therapeutics Sales Share by Manufacturers in 2021
    Figure 14. Global Anti-Obesity Therapeutics Revenue Share by Manufacturers in 2021
    Figure 15. The Global 5 and 10 Largest Anti-Obesity Therapeutics Players: Market Share by Revenue in 2021
    Figure 16. Anti-Obesity Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 17. Global Anti-Obesity Therapeutics Sales Market Share by Region (2017-2022)
    Figure 18. Global Anti-Obesity Therapeutics Sales Market Share by Region in 2021
    Figure 19. Global Anti-Obesity Therapeutics Revenue Market Share by Region (2017-2022)
    Figure 20. Global Anti-Obesity Therapeutics Revenue Market Share by Region in 2021
    Figure 21. U.S. Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 22. Canada Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 23. Germany Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 24. France Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. U.K. Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. Italy Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. Russia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. China Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. Japan Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. South Korea Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. India Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. Australia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. Taiwan Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. Indonesia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. Thailand Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. Malaysia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Philippines Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Vietnam Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Mexico Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. Brazil Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Argentina Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 42. Turkey Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 43. Saudi Arabia Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 44. U.A.E Anti-Obesity Therapeutics Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 45. Sales Market Share of Anti-Obesity Therapeutics by Type (2017-2022)
    Figure 46. Manufacturing Cost Structure of Anti-Obesity Therapeutics
    Figure 47. Manufacturing Process Analysis of Anti-Obesity Therapeutics
    Figure 48. Anti-Obesity Therapeutics Industrial Chain Analysis
    Figure 49. Channels of Distribution
    Figure 50. Distributors Profiles
    Figure 51. Bottom-up and Top-down Approaches for This Report
    Figure 52. Data Triangulation
    Figure 53. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Bristol-Myers Squibb
Eisai Company
FlaxoSithKline plc.
Novo Nordisk
Alizyme
BoehringerIngelheim GmbH
Pfizer
Takeda Pharmaceutical
Rhythm Pharmaceuticals
Shionogi USA
Vivus
Zafgen
Norgine Pharmaceuticals Ltd.
Frequently Asked Questions
Anti-Obesity Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Anti-Obesity Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Anti-Obesity Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports